IPS Genomix stands for innovation that benefits to the community. Specialized in the latest prognostic, predictive and personalized medicine, IPS Genomix gives treating physicians access to important and clinically relevant genomic information further to testing human specimens (tissue, blood, saliva, buccal swab…) in the European or US partnering laboratories accredited and specialized in this field.
The treating physician can then individualize the treatment of his/her patients to enhance the prevention and/or treatment of certain conditions and diseases. IPS Genomix brings this intelligent and groundbreaking new solution to treating physicians and their patients in the Middle East and Africa thanks to partnerships with multinational companies.
Given the rapid evolution of this particular field, IPS Genomix constantly incorporates new technology platforms and assays to offer physicians and their patients with the most up to date, reliable and cutting edge personalized medicine tools.
His vision goes over and above pharmaceutical solutions. It leads him to drive the regional market with innovative and progressive solutions. He wants IPS to “Become, with the support of its highly-experienced people, the game changers of the region.”
A strategist and a results-oriented professional, he has the essential know-how needed to grow the business and predict potential market opportunities.
He founded IPS on the belief that, “Patients are the core of our presence and if we position ourselves in their shoes, we will strive to serve them better.”